Drug Discovery & DDS Weekly Report May 7, 2026

Drug Discovery & DDS Weekly Report September 13, 2026

Eli Lilly’s Oral GLP-1 Agonist Orforglipron Shows Promising Weight Loss and Safety in Phase 2 Trials, Rivaling Injectables

US Trade Policy and BIOSECURE Act Drive Major Reshaping and Investment in Global ADC Manufacturing Landscape

Waterfall Scientific Wins Up to $54.5 Million from ARPA-H to Pioneer Continuous-Flow mRNA Manufacturing Platform

Ionis’ Zanvastro (Zilganersen) Gains FDA Approval as First Disease-Modifying ASO Therapy for Alexander Disease

Catalent Secures $4.1B Refinancing, Fuels Major Expansion in Biologics and Oral Drug Manufacturing to Meet GLP-1 Demand

Moderna’s RSV Vaccine mRESVIA® Receives FDA Approval as mRNA Therapeutics Advance in Non-Vaccine Applications

The Pharma AI Data Problem: Complex Clinical Trial Data Impedes AI Model Development and Deployment